Nuvelo, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel drugs for acute cardiovascular disease, cancer, and other debilitating medical conditions in the United States. Its development pipeline includes alfimeprase, a recombinant direct-acting fibrinolytic that is in Phase II clinical trial for the treatment of thrombotic-related disorders, such as acute ischemic stroke and catheter occlusion; NU172, a thrombin inhibiting aptamer, is in Phase I development for use as a short-acting anticoagulant during medical or surgical procedures; and NU206, a preclinical candidate for the treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease. The company also has research programs in leukemia therapeutic antibodies and Wnt signaling pathway therapeutics. Nuvelo has collaborations partnership with Amgen, Inc.; Dendreon Corporation; and Archemix Corporation. The company was founded in 1991 and is headquartered in San Carlos, California.